Concert Pharmaceuticals Profit Margin

The latest profit margin for CNCE is -117455.64% as of September 2022. That compares with -203.59% in the prior-year period — down 57593.4% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Concert Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, CNCE's profit margin moved from -203.59% to -117455.64% — a 57593.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Concert Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, CNCE currently prints -117455.64% for profit margin, while the sector average sits near 21.34%. That is roughly 550625.0% below the sector mean. Large gaps often invite a closer look at Concert Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Concert Pharmaceuticals converts resources into returns. At -117455.64%, CNCE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -203.59% in the prior-year period — down 57593.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CNCE's profit margin (-117455.64%), review year-over-year change from -203.59%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.